RET
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
RET
Jun 21, 2024, 04:15 |
Insight
Biagio Ricciuti: Fusion partners and chromosomal breakpoints of oncogenic fusions are not stochastic
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General…
Jun 10, 2024, 09:53 |
Blog
We are proud to be members of Lung Cancer Europe - Oncogene Cancer Research
Oncogene Cancer Research recently shared a post by Lung Cancer Europe on LinkedIn, adding: "We…
May 25, 2024, 11:59 |
Blog
Vivek Subbiah: ASCO 24 time to learn the latest and greatest in Tissue Agnostic Precision Medicine
Vivek Subbiah shared on X: “It's ASCO 24 time Mark your calendars to learn the latest…
May 14, 2024, 15:44 |
Blog
Stephen Liu: The latest updates on targeting RET in lung cancer
Stephen Liu shared on X/Twitter: "For the latest updates on targeting RET in lung cancer, listen…
Mar 26, 2024, 00:22 |
Opinion
Wafik S. El-Deiry: WIN Consortium in cancer personalized medicine MTB had well over 30 participants
Wafik S. El-Deiry shared on LinkedIn: "Today’s WIN Consortium in cancer personalized medicine MTB had well…
Mar 19, 2024, 03:22 |
Blog
Vivek Subbiah: Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic Pancreatic Cancer
Vivek Subbiah shared a post on X/Twitter: ''Exceptional Responses to Selpercatinib in RET Fusion–Driven Metastatic…
Mar 16, 2024, 15:39 |
Blog
Sarah Sammons: DPYD testing is required before our pharmacy will dispense capecitabine
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post by Vivek Subbiah…
Mar 8, 2024, 15:14 |
Blog
Vivek Subbiah: Harnessing the potential of basket trials
Vivek Subbiah recently shared a post on X/Twitter: "Revolutionizing cancer drug development: Harnessing the potential…
Jan 13, 2024, 10:04 |
Blog
Nathan A. Pennell: Pralsetinib development outside the US and China also stopped
Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by…
Dec 28, 2023, 07:08 |
Blog
Vivek Subbiah: TP53 is an attractive target for novel cancer therapies
Vivek Subbiah shared a post on his X/Twitter page: "Pharmacological reactivation of p53 in the…
1
2
All:
11
Posts:
1 - 10
Eliot Levitt: The Yvonne Awards demonstrate something that it doesn't hurt to be reminded of
New data from the NEST clinical trial was presented at ESMOGI24 - Agenus
Zainab Shinkafi-Bagudu's latest commentary on Cervical Cancer Elimination Forum
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer
Facebook
RSS Feed
Twitter
Linkedin
Youtube